Why AIM ImmunoTech Stock More Than Doubled Today After a Pancreatic Cancer Trial Surprise
AIM ImmunoTech Inc. shares more than doubled on Monday after the drug developer said the final planned subject in its Phase 2 DURIPANC pancreatic-cancer trial had met enrollment criteria, putting the study ahead of its earlier July target.